RenGene Bio Secures $2M Angel Funding Led by MSA Capital to Advance Large-Scale Genomic Humanization Technology for Antibody Drug Development

Beijing RenGene Biotechnology Co., Ltd. Announces Successful Completion of $2 Million Angel Financing Round, Led by MSA Capital with Follow-on Investment from CytoMed Research InstituteRenGene is a high-tech company built on a novel molecular and cellular biology technology platform. It is dedicated to developing globally leading, independently owned large-scale gene editing technologies to establish high-value animal models, thereby accelerating biomedical research and development more efficiently.

As the global trend and cornerstone of current oncology therapeutics, antibody drugs are experiencing a market explosion worth hundreds of billions of dollars. However, as the foundational platform technology for antibody development, existing gene-editing techniques face numerous challenges in constructing genomically humanized mouse platforms.

RenGene is dedicated to establishing globally leading large-scale gene editing technology, which will significantly shorten the time required to generate humanized animal models and reduce costs. This represents a technological leap forward, enabling more efficient provision of high-value-added animal models for biomedical research and development. In the short term, RenGene’s R&D efforts will focus on developing and optimizing its proprietary large-scale gene editing technology and establishing mouse models for the efficient development of single-domain antibodies. Subsequently, leveraging its unique technology platform, the company will humanize antibody-related genes in mice to establish two major mouse model platforms capable of producing high-affinity, highly diverse fully human monoclonal antibodies and fully human single-domain antibodies in vivo, thereby facilitating more efficient antibody drug development.

RenGene was founded in Beijing in early 2018 by a team of experts from the Chinese Academy of Sciences and the Academy of Military Medical Sciences. Its seed round was incubated by Beijing Saifu Pharmaceutical Research Institute. The company has established molecular and cellular laboratories as well as barrier-environment animal facilities, all of which are now fully operational. Meanwhile, RenGene has assembled an experienced team specializing in gene editing, mouse model construction, and antibody development. R&D activities are progressing smoothly, and the company expects to file multiple invention patents in the first half of 2019, covering large-scale gene editing technologies and mouse models for in vivo generation of single-domain antibodies.

In addition to investing in core technology R&D, this angel round of financing will also be used to further strengthen the R&D team and build a technical platform, thereby accelerating the R&D process and securing a first-mover advantage.

Dr. Wang, founder of Renyuan Xinsheng, stated that the company aims to establish a high-efficiency platform for new drug development, empower the pharmaceutical R&D industry, and serve human health. In the short term, Renyuan Xinsheng’s primary R&D focus is on developing and optimizing its proprietary large-fragment genomic humanization technology and establishing mouse models for the efficient development of single-domain antibodies. In the future, the company will leverage its unique technology platform to build two major mouse model platforms capable of generating high-affinity, highly diverse fully human monoclonal antibodies and fully human single-domain antibodies in vivo, thereby enabling more efficient antibody drug development.

Zeng Yu, Managing Partner at MSA Capital, stated that the fully human antibody transgenic mouse platform plays a crucial role in the development of antibody-based therapeutics. However, China currently lacks mouse platforms that meet world-class standards. Renyuan Xinsheng boasts strong R&D capabilities and, leveraging its proprietary, independently developed technology platform, holds significant application potential in fields such as biopharmaceutical research and development.

Renyuan Xinsheng is a high-tech company built on an advanced molecular and cellular biology technology platform, dedicated to the development of large-fragment genomic humanization technology with independent core intellectual property rights. This technology will significantly enhance the efficiency of constructing high-value animal models, supporting R&D in hot biomedical fields such as antibody drugs and cell therapy. Currently, all members of the company’s R&D team hold master’s degrees or higher. The Chief Scientist has devoted many years to gene editing and animal model construction and is one of the global pioneers in applying gene-editing technologies to animal model development. The company has also recruited an R&D Director from overseas with extensive experience in antibody development, and has specially engaged experts from research institutes and universities, including the Academy of Military Medical Sciences, as consultants to ensure the smooth progress of its R&D efforts.

Hegu Capital（MSA Capital is a private equity investment firm with assets under management exceeding USD 1 billion. MSA Capital has consistently focused on in-depth analysis and top-down research, completing over 80 investments in the TMT and healthcare sectors. The firm possesses extensive and profound insights and practical experience across all segments of the investment ecosystem. Key direct investment projects include:

Meituan Dianping (SEHK: 03690), NIO Inc. (NYSE: NIO), BGI Genomics (SZ: 300676), PinTec (NASDAQ: PT), Mogujie (NYSE: MOGU), Uber, Yidu Cloud, BOSS Zhipin, Mobike, Zhaogang.com, Xiaozhu, Shusong Pinpin, etc.